Phase I Study of Cellular Immunotherapy Using Central Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma

Trial Profile

Phase I Study of Cellular Immunotherapy Using Central Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs MB 101 (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Dec 2016 Single patient data prompted the expansion of this study to evaluate intraventricular administration in a larger cohort of patients, as per a Fortess Biotech media release.
    • 28 Dec 2016 A patient case study results published in a Fortess Biotech media release.
    • 28 Dec 2016 A patient case study details will be published in the December 29 edition of the New England Journal of Medicine, as per a Fortess Biotech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top